FuturHealth vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
FuturHealth
Best for readers who want both brand-name and compounded GLP-1 options on one platform with registered-dietitian nutrition coaching, AND are willing to read the data-breach litigation disclosure before signing upStarting at $199/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | FuturHealth | Wisp |
|---|---|---|
| Overall Score | 6.7/10 | ✓7.0/10 |
| Starting Price | ✓$199/mo | $225/mo |
| Editorial Rating | 3.4 ★ /5 | ✓3.5 ★ /5 |
| Features | ✓8 features | 6 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
FuturHealth
Pros
- ✓LegitScript Certified and HITRUST Certified — two independently verifiable telehealth/health-data trust marks
- ✓Both brand-name (Ozempic, Wegovy, Mounjaro, Zepbound) and clinician-discretionary compounded options on one platform
- ✓Bundled registered-dietitian nutrition guidance — most pure-Rx telehealths leave nutrition support to the patient
Cons
- ✗ACTIVE LITIGATION: Wilson v. FuturHealth Inc., U.S. District Court Southern District of California, Case No. 3:2025cv00157, alleging unauthorized access to G-Plans subscriber data on/before October 16, 2024 and asserting CCPA, medical-confidentiality, and negligence claims. Material disclosure for any reader signing up.
- ✗BBB complaint pattern: multiple consumer reports of recurring unauthorized charges (e.g. $396/month) without medication being received — verify cancellation flow before subscribing
- ✗Pharmacy partners are described as 'licensed, U.S.-based pharmacies' but no specific 503A/503B partners are publicly named
- ✗Pricing is not displayed on the public landing page — visible only after qualification questionnaire/portal login
- ✗Clinical platform is white-labeled on top of SteadyMD and OpenLoop infrastructure — FuturHealth is the front-end brand, not the first-party prescribing entity
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
Wisp edges out FuturHealth with a higher overall score of 7.0/10 and is particularly strong for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested. FuturHealth remains a solid alternative, especially if you're looking for readers who want both brand-name and compounded GLP-1 options on one platform with registered-dietitian nutrition coaching, AND are willing to read the data-breach litigation disclosure before signing up.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.